Study administered broadly neutralizing antibody infusions to virally suppressed volunteers who initiated ART during acute HIV infection
July 25, 2017 (PARIS) — A new study has shown that infusion of a broadly neutralizing antibody (bNAb) in virally suppressed, early treated volunteers was associated with a modestly delayed rebound of HIV after interruption of antiretroviral therapy (ART). The study, the first randomized controlled trial to demonstrate this effect of VRC01, was led by the U.S. Military HIV Research Program (MHRP) of the Walter Reed Army Institute of Research (WRAIR) and the Thai Red Cross AIDS Research Centre. MHRP presented findings from the study today at the 9 the IAS Conference on HIV Science in Paris, France.
VRC01 Antibody Prolonged Time to HIV Viral Rebound After Treatment Interruption. Study administered broadly neutralizing antibody infusions to virally suppressed volunteers who initiated ART during acute HIV infection.
